Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS
Inovio Pharmaceuticals Inc. logo

Inovio Pharmaceuticals Inc.

Sector: Healthcare   

Industry: Biotechnology

10.16
 
USD
  
-0.21
  
(-2.03%)
Optionable: Yes  Market Cap: 242 M  90-day average vol: 483,769

Previous close: 10.37  Open: 10.42  Bid: 10.05  Ask: 10.2
52 week range    
3.89   
   14.75
Peers   
PFE / 
JNJ / 
ARWR / 
NVS / 
MRK / 
DRRX / 
GILD / 
Last updated: Thursday 25th April 2024
40
MarketXLS Rank
60
Value
30
Technical
31
Quality

Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS

Get started today
Search for a stock

🎉 Exciting news! 🎉

You are invited to join our Discord Channel.

Interact, learn, and grow with experts in the markets!

Join our Discord

Metrics

Peers

StockDividendMarket Cap (B)PEPrice ($)

ARWR

6 B-38.852.1

DRRX

0 B-6.90.723

GILD

0.044486 B11.763.76

GSK

JNJ

0.0247450 B22.1171.06

MRK

0.0356207 B28.877.58

NVS

PFE

0.0302298 B15.153.21
Financials

INO Income Statement

Annual
Dec-14Dec-15Dec-16Dec-17Dec-18Dec-19Dec-20Dec-21Dec-22Dec-23
AcquiredInProcessRnD-7 M
AcquiredInProcessRnDIncome348143.0
Amortization of intangibles-942719.0-870199.0-1 M-2 M-1 M11 M11 M11 M11 M
Basic EPS from continuing operations-1.08-1.05-1.21-1.07-1.45-14.04-6.09
Basic EPS total-0.61-0.43-1.01-1.08-1.05-1.21-1.07-1.45-14.04-6.09
Basic weighted shares outstanding59 M68 M73 M82 M93 M99 M155 M209 M20 M22 M
Depreciation-626554.0-1 M-2 M-2 M-4 M4 M3 M3 M4 M3 M
DepreciationAndAmortization-626554.0-1 M-2 M-2 M-4 M4 M3 M3 M4 M3 M
Diluted EPS total-0.64-0.44-1.01-1.09-1.05-1.21-1.07-1.45-14.04-6.09
Diluted normalized net income/share-1.09-1.05-1.21-1.45-14.04-6.09
Diluted weighted shares outstanding59 M68 M73 M82 M93 M99 M155 M209 M20 M22 M
Earnings from equity interest-7 M-5 M-434387.0-2 M
EarningsFromEquityInterestNetOfTax-7 M-5 M-434387.0-2 M
GainOnSaleOfBusiness3 M4 M
GainOnSaleOfPPE501000.01000000.01000000.01000000.00.06000.0227000.089000.01 M466000.0
GainOnSaleOfSecurity34000.0151000.0139000.00.020000.0-2 M-76 M394000.021000.01000.0
GeneralAndAdministrativeExpense16 M18 M24 M28 M29 M27 M37 M54 M90 M48 M
Gross operating profit10 M41 M35 M42 M30 M4 M7 M2 M10 M832010.0
ImpairmentOfCapitalAssets11 M
Income before tax-36 M-31 M-74 M-88 M-95 M-121 M-163 M-303 M-278 M-135 M
Income taxes-27000.0-2 M-501000.0-50 M2 M-257335.0-3 M-4 M-4 M
Interest income331461.0305071.01 M2 M0.0
InterestExpenseNonOperating0.08 M9 M2 M1 M1 M
InterestIncomeOperating2 M3 M3 M3 M5 M8 M
MinorityInterests18420.0-84769.00.01 M1 M400 M
MiscOtherSpecialCharges3 M-722000.01 M15 M-3 M496200.0-704896.0343371.0-4 M-5 M
Net income from total operations-36 M-29 M-74 M-88 M-97 M-119 M-166 M-304 M-280 M-135 M
NetIncomeCommonStockholders-36 M-29 M-74 M-88 M-97 M-116 M-204 M-303 M-280 M-135 M
NetIncomeContinuousOperations-36 M-29 M-74 M-88 M-97 M-119 M-166 M-304 M-280 M-135 M
NetIncomeFromOtherGainsLosses3 M
NetNonOperatingInterestIncomeExpense331461.03 M1 M2 M360795.0-8 M-9 M-2 M-1 M-1 M
Normalized income-307 M-129 M
Operating income-39 M-35 M-77 M-85 M-94 M-111 M-124 M-301 M-268 M-144 M
Operating income before depreciation (EBITDA)-34 M-29 M-70 M-84 M-90 M-107 M-150 M-297 M-271 M-130 M
OperatingExpense-50 M-75 M-112 M127 M125 M115 M131 M303 M278 M145 M
Other income net-3 M-1 M-2 M5 M3 M1 M75 M3 M14 M-1 M
OtherGandA16 M18 M24 M28 M29 M27 M37 M54 M90 M48 M
OtherImpairmentOfCapitalAssets-274000.0
OtherOperatingExpenses-50 M-75 M-112 M-126 M-125 M-2 M-1 M-7 M-3 M-2 M
RealizedCapitalGain-2 M
RentAndLandingFees16 M18 M24 M-2 M0.0
Research & development expense34 M58 M89 M99 M95 M88 M94 M249 M188 M87 M
ResearchExpense34 M58 M89 M99 M95 M88 M94 M249 M188 M87 M
Revenue per share-942719.0-870199.0-1 M-2 M-1 M11 M11 M11 M11 M
SalariesAndWages-5 M-6 M-10 M-13 M-11 M11 M16 M26 M
Selling Gen & administrative expense16 M18 M24 M28 M29 M27 M37 M54 M90 M48 M
Special income/charges215000.01 M-11 M
Total Income available for interest expense (EBIT)-36 M-31 M-74 M-88 M-95 M-113 M-154 M-301 M-276 M-134 M
Total common shares outstanding61 M72 M74 M90 M98 M146 M208 M217 M22 M23 M
Total net income-36 M-29 M-74 M-88 M-97 M-119 M-166 M-304 M-280 M-135 M
Total ordinary shares23 M23 M23 M23 M23 M23 M23 M23 M23 M23 M
Total revenues10 M41 M35 M42 M30 M4 M7 M2 M10 M832010.0
TotalExpenses-50 M-75 M-112 M127 M125 M115 M131 M303 M278 M145 M
TotalRevenue10 M41 M35 M42 M30 M4 M7 M2 M10 M832010.0
WriteDown-215000.00.0
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.

MarketXLS is a complete Excel stock solution

Kevin Hsu

StockKevin.com

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel

Lloyd Lenase

Option Day Trader

MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.

Dave

Swing trader since 2011

I like to access historical closing prices on a particular date. That makes tracking performance easy.

Patrick Cusatis, Ph.D., CFA

Associate Professor of Finance - Penn State University